Researchers develop Ebola treatment effective three days after infection

April 22, 2015, University of Texas Medical Branch at Galveston
Lead UTMB author Thomas Geisbert. Credit: The University of Texas Medical Branch at Galveston

Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa.

The study results, in the April 22 edition of Nature journal, demonstrated that the treatment is the first to be shown effective against the new Makona outbreak strain of Ebola in animals that were infected with the virus and exhibited symptoms of the disease.

The treatment uses a sequence specific short strand of RNA, known as siRNA, designed to target and interfere with the Ebola virus, rendering it harmless. One of the advantages of this approach is the ability to quickly modify it to different viral strains.

"We quickly adapted our candidate treatment to target the Makona outbreak strain of Ebola virus," said UTMB's Thomas Geisbert, professor of microbiology and immunology. "We were able to protect all of our nonhuman primates against a lethal Makona Ebola infection when treatment began three days following infection. At this point, those infected showed clinical signs of disease and had detectable levels of virus in their blood."

Although all infected animals showed evidence of advanced disease, those receiving treatment had milder symptoms and recovered fully. The untreated controls succumbed to the disease on days eight and nine, which is similar to that reported in the field after patients begin showing symptoms of Ebola.

This treatment also protected against liver and kidney dysfunction and blood disorders that occur during an Ebola infection. These results indicate that the may confer protective benefits that go beyond improving survival rates and effective control of virus levels in the body.

"This study demonstrates that we can rapidly and accurately adapt our siRNA-LNP technology to target genetic sequences emerging from new Ebola outbreaks," said Dr. Mark Murray, president and CEO of Tekmira Pharmaceuticals.

The Tekmira siRNA-based therapeutic is now being evaluated in Ebola-infected patients in Sierra Leone.

Explore further: Researchers develop Ebola vaccine effective in a single dose

More information: Nature, DOI: 10.1038/nature14442

Related Stories

Researchers develop Ebola vaccine effective in a single dose

April 8, 2015
An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola ...

Tekmira will resume safety study of Ebola drug within weeks

April 10, 2015
Canadian drugmaker Tekmira Pharmaceuticals said Friday it will restart a study of an experimental Ebola treatment in the coming weeks.

Team develops treatment effective against lethal Marburg virus

August 20, 2014
For the first time, researchers at the University of Texas Medical Branch at Galveston, in collaboration with Tekmira Pharmaceuticals, have protected nonhuman primates against Marburg virus – Angola hemorrhagic fever. Their ...

US Ebola patient's condition improves: NIH

March 26, 2015
An American healthcare worker in treatment after becoming infected with the Ebola virus in Sierra Leone has improved and is now in serious condition, the National Institutes of Health said Thursday.

Leading Ebola researcher says there's an effective treatment

August 29, 2014
A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola ...

Ebola vaccine trial begins in Sierra Leone

April 14, 2015
Thousands of healthcare workers in areas of Sierra Leone that are grappling with Ebola will now begin receiving an experimental vaccine against the often deadly virus, officials said Tuesday.

Recommended for you

Deadly Rift Valley fever: New insight, and hope for the future

July 19, 2018
Health control measures alone could be ineffective in the long term fight against the deadly Rift Valley fever which affects both humans and animals, a new study in the journal PNAS reports.

New guidelines to diagnose, manage rare endocrine disorders

July 19, 2018
International guidelines have been published for the first time to help doctors around the globe diagnose and manage patients with a very rare set of endocrine diseases known as pseudohypoparathyroidism and its related disorders, ...

Overuse of antibiotics not what the doctor ordered

July 19, 2018
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community ...

Alcohol-related cirrhosis deaths skyrocket in young adults

July 18, 2018
Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.

Hidden blood in feces may signal deadly conditions

July 17, 2018
(HealthDay)—Even if it's not visible to the naked eye, blood in the stool can be serious—a sign of a potentially fatal disease other than colon cancer, new research suggests.

Childhood abuse linked to greater risk of endometriosis, study finds

July 17, 2018
Endometriosis, a painful condition that affects one in 10 reproductive-age women in the U.S., has been linked to childhood physical and sexual abuse, according to findings published today in the journal Human Reproduction.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.